Apheresis in Neurological Disorders
Apheresis refers to an extracorporeal therapy which aims at removing pathological constituents from the patients’ blood. Due to the development of new techniques as well as the discovery of novel autoimmune antibodies, it is increasingly recognized as an important therapeutic option for a variety of...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2020 |
| Language: | English |
| Physical Description: | 1 electronic resource (174 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993546102304498 |
|---|---|
| ctrlnum |
(CKB)5400000000040973 (oapen)https://directory.doabooks.org/handle/20.500.12854/69367 (EXLCZ)995400000000040973 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Dorst, Johannes edt Apheresis in Neurological Disorders Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (174 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Open access Unrestricted online access star Apheresis refers to an extracorporeal therapy which aims at removing pathological constituents from the patients’ blood. Due to the development of new techniques as well as the discovery of novel autoimmune antibodies, it is increasingly recognized as an important therapeutic option for a variety of autoimmune-mediated neurological disorders, including multiple sclerosis, myasthenia gravis, autoimmune encephalitis, Guillain–Barré syndrome, and many others. Therapeutic plasma exchange (TPE) constitutes the standard method of apheresis for most indications, while immunoadsorption (IA) offers a more specific, low-risk alternative. Both methods aim at removing auto-antibodies from the blood. Evidence for most neurological diseases is still low. Interestingly, more recent developments suggest that apheresis is not limited to the removal of autoantibodies but may also be useful in neurodegenerative and possibly even in acute vascular disorders. English Medicine bicssc immunoadsorption acute relapsing multiple sclerosis plasma exchange therapeutic apheresis multiple sclerosis optic neuritis relapse class IV steroids Alzheimer's clinical syndrome dementia autoantibodies α1-Adrenergic receptor Inflammatory neuropathy chronic inflammatory demyelinating polyneuropathy Guillain-Barré syndrome paranodal antibodies plasmapheresis Myalgic Encephalomyelitis/Chronic Fatigue Syndrome ß2 adrenoreceptor autoantibody autoimmune encephalitis limbic encephalitis NMDAR (N-Methyl-D-Aspartat) antibody paraneoplastic apheresis therapeutic plasma exchange neurological diseases CRP stroke inflammation 3-03943-585-X 3-03943-586-8 Dorst, Johannes oth |
| language |
English |
| format |
eBook |
| author2 |
Dorst, Johannes |
| author_facet |
Dorst, Johannes |
| author2_variant |
j d jd |
| author2_role |
Sonstige |
| title |
Apheresis in Neurological Disorders |
| spellingShingle |
Apheresis in Neurological Disorders |
| title_full |
Apheresis in Neurological Disorders |
| title_fullStr |
Apheresis in Neurological Disorders |
| title_full_unstemmed |
Apheresis in Neurological Disorders |
| title_auth |
Apheresis in Neurological Disorders |
| title_new |
Apheresis in Neurological Disorders |
| title_sort |
apheresis in neurological disorders |
| publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
| publishDate |
2020 |
| physical |
1 electronic resource (174 p.) |
| isbn |
3-03943-585-X 3-03943-586-8 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT dorstjohannes apheresisinneurologicaldisorders |
| status_str |
n |
| ids_txt_mv |
(CKB)5400000000040973 (oapen)https://directory.doabooks.org/handle/20.500.12854/69367 (EXLCZ)995400000000040973 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Apheresis in Neurological Disorders |
| author2_original_writing_str_mv |
noLinkedField |
| _version_ |
1789661290990403584 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03053nam-a2200673z--4500</leader><controlfield tag="001">993546102304498</controlfield><controlfield tag="005">20240129142223.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000040973</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/69367</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000040973</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dorst, Johannes</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Apheresis in Neurological Disorders</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (174 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Open access</subfield><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Apheresis refers to an extracorporeal therapy which aims at removing pathological constituents from the patients’ blood. Due to the development of new techniques as well as the discovery of novel autoimmune antibodies, it is increasingly recognized as an important therapeutic option for a variety of autoimmune-mediated neurological disorders, including multiple sclerosis, myasthenia gravis, autoimmune encephalitis, Guillain–Barré syndrome, and many others. Therapeutic plasma exchange (TPE) constitutes the standard method of apheresis for most indications, while immunoadsorption (IA) offers a more specific, low-risk alternative. Both methods aim at removing auto-antibodies from the blood. Evidence for most neurological diseases is still low. Interestingly, more recent developments suggest that apheresis is not limited to the removal of autoantibodies but may also be useful in neurodegenerative and possibly even in acute vascular disorders.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunoadsorption</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acute relapsing multiple sclerosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">plasma exchange</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic apheresis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multiple sclerosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">optic neuritis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">relapse</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">class IV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">steroids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Alzheimer's clinical syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dementia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autoantibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">α1-Adrenergic receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Inflammatory neuropathy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic inflammatory demyelinating polyneuropathy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Guillain-Barré syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">paranodal antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">plasmapheresis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ß2 adrenoreceptor autoantibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autoimmune encephalitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">limbic encephalitis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NMDAR (N-Methyl-D-Aspartat)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">paraneoplastic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">apheresis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic plasma exchange</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurological diseases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CRP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stroke</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-585-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03943-586-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dorst, Johannes</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-01-31 22:27:38 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338113250004498&Force_direct=true</subfield><subfield code="Z">5338113250004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338113250004498</subfield></datafield></record></collection> |